-
Perilymphatic regulatory T cell-dendritic cell interactions represent a novel axis of immunosuppression in cancer Cancer Cell (IF 48.8) Pub Date : 2024-07-18
Dendritic cells are critical inducers of adaptive anti-tumor immunity. However, their maturation, activation, and migration are often compromised in the tumor microenvironment. In this issue, You et al. demonstrate a novel axis of suppression of dendritic cell function mediated by interaction with regulatory T cells in perilymphatic niches.
-
Transcription factor dependencies identify BAF-dependent cancers Cancer Cell (IF 48.8) Pub Date : 2024-07-18
In Cancer Cell, Bolomsky et al., Duplaquet et al., and He et al. identify cancers that are dependent on the BAF chromatin remodeling complex, specifically IRF4-driven multiple myeloma and POU2F3-subtype small cell lung cancer, highlighting potential therapeutic applications for BAF complex inhibitors/degraders.
-
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies Cancer Cell (IF 48.8) Pub Date : 2024-07-18
-
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer Cancer Cell (IF 48.8) Pub Date : 2024-07-18
-
Tumor-infiltrating lymphocytes: A new hope Cancer Cell (IF 48.8) Pub Date : 2024-07-18
Tumor-infiltrating lymphocytes (TILs) can be massively expanded from resected tumors and used as a cellular treatment for advanced malignancies. TILs require a preparative non-myeloablative chemotherapy followed by an abbreviated course of interleukin-2. Here, we review the historical development of TIL therapy and discuss potential solutions to ongoing roadblocks that may result in broader and improved
-
Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity Cancer Cell (IF 48.8) Pub Date : 2024-07-18
-
Immune cell triads reprogram exhausted CD8+ T cells for effective tumor elimination Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Veronica Lise, Ines Malenica, Rahul Roychoudhuri, Enrico Lugli
In this issue of Cancer Cell, Espinosa-Carrasco et al. show that the efficacy of cancer immunotherapies depends upon the formation of intratumoral immune triads between antigen-presenting cells and antigen-specific CD4+ and CD8+ T cells. This interaction reprograms tumor-specific CD8+ T cells to exert potent effector functions and eradicate established solid tumors.
-
Medulloblastoma subgrouping at first sight Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Marc Remke, Vijay Ramaswamy
Recent incorporation of the four primary medulloblastoma subgroups into the WHO Classification of Central Nervous System Tumors necessitates globally accessible methods to discern subgroups. In this issue of Cancer Cell, Wang et al. develop a rapid and reliable machine learning workflow for pre-operative subgroup determination using routine magnetic resonance imaging.
-
HRS-4642: The next piece of the puzzle to keep KRAS in check Cancer Cell (IF 48.8) Pub Date : 2024-07-08
KRASG12D is the most frequent KRAS mutation in human cancer. In this issue, Zhou et al. describe a novel KRASG12D inhibitor, HRS-4642, that shows pote…
-
Casting a wider net: The clinical potential of EV transcriptomics in multi-analyte liquid biopsy Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Yari Ciani, Caterina Nardella, Francesca Demichelis
Cancer cells release cell-free DNA (cfDNA) and extracellular vesicles (EVs) into the bloodstream, allowing disease non-invasive monitoring. In this issue of Cancer Cell, Casanova-Salas et al. analyze cfDNA, EV-DNA, and EV-RNA in prostate cancer longitudinal cohorts treated with androgen receptor signaling inhibitors and taxanes, identifying signals reflecting tumor adaptation processes.
-
Multi-scale signaling and tumor evolution in high-grade gliomas Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Jingxian Liu, Song Cao, Kathleen J. Imbach, Marina A. Gritsenko, Tung-Shing M. Lih, Jennifer E. Kyle, Tomer M. Yaron-Barir, Zev A. Binder, Yize Li, Ilya Strunilin, Yi-Ting Wang, Chia-Feng Tsai, Weiping Ma, Lijun Chen, Natalie M. Clark, Andrew Shinkle, Nataly Naser Al Deen, Wagma Caravan, Andrew Houston, Faria Anjum Simin, Li Ding
-
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Yuqing Chen, Dongfang Wang, Yingjie Li, Lu Qi, Wen Si, Yufei Bo, Xueyan Chen, Zhaochen Ye, Hongtao Fan, Baolin Liu, Chang Liu, Li Zhang, Xiaoyan Zhang, Zhongwu Li, Linna Zhu, Aiwen Wu, Zemin Zhang
-
Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Irene Casanova-Salas, Daniel Aguilar, Sarai Cordoba-Terreros, Laura Agundez, Julian Brandariz, Nicolas Herranz, Alba Mas, Macarena Gonzalez, Rafael Morales-Barrera, Alexandre Sierra, Mario Soriano-Navarro, Pablo Cresta, Gisela Mir, Sara Simonetti, Gonçalo Rodrigues, Sara Arce-Gallego, Luisa Delgado-Serrano, Irene Agustí, Elena Castellano-Sanz, Richard Mast, Joaquin Mateo
-
Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors Cancer Cell (IF 48.8) Pub Date : 2024-07-08 Yong Lu, Qiang Wang, Gang Xue, Enguang Bi, Xingzhe Ma, Aibo Wang, Jianfei Qian, Chen Dong, Qing Yi
No Abstract
-
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression Cancer Cell (IF 48.8) Pub Date : 2024-05-30 Pradip K. Majumder, Chiara Grisanzio, Fionnuala O’Connell, Marc Barry, Joseph M. Brito, Qing Xu, Isil Guney, Raanan Berger, Paula Herman, Rachel Bikoff, Giuseppe Fedele, Won-Ki Baek, Shunyou Wang, Katharine Ellwood-Yen, Hong Wu, Charles L. Sawyers, Sabina Signoretti, William C. Hahn, Massimo Loda, William R. Sellers
No Abstract
-
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer Cancer Cell (IF 48.8) Pub Date : 2024-06-27 Caicun Zhou, Chongyang Li, Libo Luo, Xin Li, Keyi Jia, Ning He, Shiqi Mao, Wanying Wang, Chuchu Shao, Xinyu Liu, Kan Huang, Yaxin Yu, Xinlei Cai, Yingxue Chen, Zican Dai, Wei Li, Jia Yu, Jiayu Li, Feng Shen, Zaiyong Wang, Shengxiang Ren
-
Advancing presurgical non-invasive molecular subgroup prediction in medulloblastoma using artificial intelligence and MRI signatures Cancer Cell (IF 48.8) Pub Date : 2024-06-27 Yan-Ran (Joyce) Wang, Pengcheng Wang, Zihan Yan, Quan Zhou, Fatma Gunturkun, Peng Li, Yanshen Hu, Wei Emma Wu, Kankan Zhao, Michael Zhang, Haoyi Lv, Lehao Fu, Jiajie Jin, Qing Du, Haoyu Wang, Kun Chen, Liangqiong Qu, Keldon Lin, Michael Iv, Hao Wang, Jian Gong
-
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma Cancer Cell (IF 48.8) Pub Date : 2024-06-20 Arnold Bolomsky, Michele Ceribelli, Sebastian Scheich, Kristina Rinaldi, Da Wei Huang, Papiya Chakraborty, Lisette Pham, George W. Wright, Tony Hsiao, Vivian Morris, Jaewoo Choi, James D. Phelan, Ronald J. Holewinski, Thorkell Andresson, Jan Wisniewski, Deanna Riley, Stefania Pittaluga, Elizabeth Hill, Craig J. Thomas, Jagan Muppidi, Ryan M. Young
-
How can we integrate the biology of breast cancer cell dormancy into clinical practice? Cancer Cell (IF 48.8) Pub Date : 2024-06-20 Islam E. Elkholi, April A.N. Rose, Julio A. Aguirre-Ghiso, Jean-François Côté
Clinical practice and clinical research heavily rely on primary tumors, circulating tumor DNA, and/or overt metastases as sources of material for predicting or investigating breast cancer metastatic relapses. However, these approaches do not consider emerging fundamentals in the biology of metastatic dormancy and relapse. Conversely, the field of metastatic dormancy often discounts key clinical factors
-
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors Cancer Cell (IF 48.8) Pub Date : 2024-06-20 Gabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, Paul Zumbo, Asim Dave, Doron Betel, Sung Wook Kang, Hee-Jin Jang, Matthew D. Hellmann, Bryan M. Burt, Hyun-Sung Lee, Andrea Schietinger
-
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial Cancer Cell (IF 48.8) Pub Date : 2024-06-20 Qing Zhou, Yi Pan, Xuening Yang, Yanqiu Zhao, Guang Han, Qingsong Pang, Zhenfa Zhang, Qifeng Wang, Jun Yao, Hui Wang, Weihua Yang, Baogang Liu, Qixun Chen, Xianghui Du, Kaican Cai, Baosheng Li, Yunchao Huang, Xiao Li, Li Song, Wei Shi, Yi-Long Wu
-
Bacteria in metastatic sites: Unveiling hidden players in cancer progression Cancer Cell (IF 48.8) Pub Date : 2024-06-13 Philippe Stevens, Elena Benidovskaya, Veronica Llorens-Rico, Jeroen Raes, Marc Van Den Eynde
Bacteria exhibit key features of cancer metastasis, such as motility, invasion, and modulation of the tumor microenvironment. They migrate through lymphatic and blood systems, invade metastatic tissues, and alter local microenvironments to support metastatic growth. Bacteria also shape the tumor microenvironment, affecting immune responses and inflammation, which influence tumor progression and therapy
-
Artificial intelligence Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Moritz Gerstung, David Liu, Marzyeh Ghassemi, James Zou, Diego Chowell, Jonas Teuwen, Faisal Mahmood, Jakob Nikolas Kather
Experts discuss the challenges and opportunities of using artificial intelligence (AI) to study the evolution of cancer cells and their microenvironment, improve diagnosis, predict treatment response, and ensure responsible implementation in the clinic.
-
Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Olga Kholmanskikh Van Criekingen, Simone Koole, David M. Thomas, Hans Gelderblom
Various tests based on different biomarkers have been developed to identify the best candidates for poly(ADP-ribose) polymerase (PARP)-inhibitor therapy. However, due to the absence of harmonization regarding these complex biomarkers, along with various cutoff points and unknown spatial and temporal variations, it is difficult to define the clinical utility of each test and ensure uniformity in treatment
-
Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Robert Saddawi-Konefka, Shiruyeh Schokrpur, J. Silvio Gutkind
Solid cancers often progress via metastasis to lymph nodes. Consequently, lymphadenectomy is central to stage cancers and eradicates disease spread. However, mounting evidence suggests that cancer immunotherapies drive antitumor immune responses within lymph nodes. This implies that immunotherapy, delivered with standard oncologic therapies, may require specific treatment sequencing to initiate immunosurveillance
-
Mapping myeloid cell function: Spatial diversity in tumor and neuronal microenvironment Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Giulia Villa, Daniel Delev, Dieter Henrik Heiland
In this issue of Cancer Cell, Zhong et al. explore the dual role of TREM2 in glioblastoma-associated myeloid cells, demonstrating its function in promoting inflammation at the tumor-neural interface and suppression within the tumor core, influenced by the local microenvironment. These findings open up promising prospects for advancements in neuro-oncological immunotherapy.
-
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Abir Hussein, Slava Stamova, Maria Xydia, Philipp Beckhove
Cancer immunotherapy is a pillar of clinical oncology but only achieves long-term remissions in a minority of cases. In this issue, van Elsas et al. show that effective immunotherapy requires a series of processes orchestrated by CD8+ T cells that result in the recruitment and local activation of M1-like macrophages.
-
Breaking up the CD8+ T cell: Treg pas de deux Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Chenyu Zhang, Alissa Bockman, Michel DuPage
Checkpoint blockade immunotherapies, such as anti-programmed death-1 (PD-1), unleash anti-tumor CD8+ T cell responses but may also induce immunosuppressive regulatory T cells (Tregs). In this issue of Cancer Cell, Geels et al. uncover that anti-PD-1 leads to Treg expansion via interleukin-2 (IL-2)-producing CD8+ T cells. Combining anti-PD-1 with anti-ICOSL interrupts this crosstalk, thereby enhancing
-
Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Naiara Perurena, Karen Cichowski
The development of mutant-selective KRAS inhibitors represents a major therapeutic advance; however, patients can develop resistance through feedback mechanisms and genetic alterations in the RAS pathway. Three publications in Nature and Cancer Discovery describe a promising RAS(ON) multi-selective inhibitor that simultaneously targets oncogenic RAS and multiple potential resistance mechanisms while
-
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Clémentine Sarkozy, Shaocheng Wu, Katsuyoshi Takata, Tomohiro Aoki, Susana B. Neriah, Katy Milne, Talia Goodyear, Celia Strong, Tashi Rastogi, Laura K. Hilton, Daniel Lai, Laurie H. Sehn, Pedro Farinha, Brad H. Nelson, Andrew Weng, Marco Marra, David W. Scott, Jeffrey W. Craig, Christian Steidl, Andrew Roth
-
Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Shannon N. Geels, Alexander Moshensky, Rachel S. Sousa, Claire Murat, Matias A. Bustos, Benjamin L. Walker, Rima Singh, Stacey N. Harbour, Giselle Gutierrez, Michael Hwang, Thorsten R. Mempel, Casey T. Weaver, Qing Nie, Dave S.B. Hoon, Anand K. Ganesan, Shivashankar Othy, Francesco Marangoni
-
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation Cancer Cell (IF 48.8) Pub Date : 2024-06-10 Hui Feng, David L. Stachura, Richard M. White, Alejandro Gutierrez, Lu Zhang, Takaomi Sanda, Cicely A. Jette, Joseph R. Testa, Donna S. Neuberg, David M. Langenau, Jeffery L. Kutok, Leonard I. Zon, David Traver, Mark D. Fleming, John P. Kanki, A. Thomas Look
No Abstract
-
Engineering focusing on cancer Cancer Cell (IF 48.8) Pub Date : 2024-06-06 Kayvan R. Keshari, Daniel A. Heller, Rostislav Boltyanskiy, Hedvig Hricak, Thomas Magaldi, Michael Overholtzer
While cancer research and care have benefited from revolutionary advances in the ability to manipulate and study living systems, the field is limited by a lack of synergy to leverage the power of engineering approaches. Cancer engineering is an emerging subfield of biomedical engineering that unifies engineering and cancer biology to better understand, diagnose, and treat cancer. We highlight cancer
-
RNA vaccines for cancer: Principles to practice Cancer Cell (IF 48.8) Pub Date : 2024-06-06 Pablo Guasp, Charlotte Reiche, Zachary Sethna, Vinod P. Balachandran
Vaccines are the most impactful medicines to improve health. Though potent against pathogens, vaccines for cancer remain an unfulfilled promise. However, recent advances in RNA technology coupled with scientific and clinical breakthroughs have spurred rapid discovery and potent delivery of tumor antigens at speed and scale, transforming cancer vaccines into a tantalizing prospect. Yet, despite being
-
Engineering cancer’s end: An interdisciplinary approach to confront the complexities of cancer Cancer Cell (IF 48.8) Pub Date : 2024-06-06 Elsa R. Flores, W. Gregory Sawyer
Cancer engineering is an interdisciplinary approach that promises to confront the complexities of cancer and accelerate transformative discoveries by integrating innovative fields across engineering and the physical sciences with a focus on cancer. We offer a conceptual framework for the hallmarks of cancer engineering, integrating 12 fields: system dynamics; imaging, radiation, and spectroscopy; robotics
-
The temporal progression of lung immune remodeling during breast cancer metastasis Cancer Cell (IF 48.8) Pub Date : 2024-05-30 Christopher S. McGinnis, Zhuang Miao, Daphne Superville, Winnie Yao, Andrei Goga, Nathan E. Reticker-Flynn, Juliane Winkler, Ansuman T. Satpathy
-
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice Cancer Cell (IF 48.8) Pub Date : 2024-05-30 Jean-Philippe Gratton, Michelle I. Lin, Jun Yu, Erik D. Weiss, Zao Li Jiang, Todd A. Fairchild, Yasuko Iwakiri, Roberto Groszmann, Kevin P. Claffey, Yung-Chi Cheng, William C. Sessa
No Abstract
-
Identification of specific PP2A complexes involved in human cell transformation Cancer Cell (IF 48.8) Pub Date : 2024-05-30 Wen Chen, Richard Possemato, K. Thirza Campbell, Courtney A. Plattner, David C. Pallas, William C. Hahn
No Abstract
-
Neural deception: Breast cancer co-opts neuronal mechanisms to evade the immune system Cancer Cell (IF 48.8) Pub Date : 2024-05-30 Nikolas Layer, Lukas Bunse, Varun Venkataramani
Cellular mechanisms mediating immunotherapy resistances are incompletely understood. In this issue, Li et al. reveal how breast cancer hijacks neuronal mechanisms of neuroprotection to shield itself from the immune system. Secretion of N-acetylaspartate impairs immune synapse formation in both neuroinflammation and breast cancer models, paving the way for novel therapeutic approaches.
-
Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite Cancer Cell (IF 48.8) Pub Date : 2024-05-30 Yihong Li, Min Huang, Minger Wang, Yi Wang, Peng Deng, Chunni Li, Jingying Huang, Hui Chen, Zhihao Wei, Qian Ouyang, Jinghua Zhao, Yiwen Lu, Shicheng Su
-
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer Cancer Cell (IF 48.8) Pub Date : 2024-05-23 John B. Finlay, Abbie S. Ireland, Sarah B. Hawgood, Tony Reyes, Tiffany Ko, Rachelle R. Olsen, Ralph Abi Hachem, David W. Jang, Diana Bell, Joseph M. Chan, Bradley J. Goldstein, Trudy G. Oliver
-
Distinct roles of TREM2 in central nervous system cancers and peripheral cancers Cancer Cell (IF 48.8) Pub Date : 2024-05-23 Jian Zhong, Xudong Xing, Yixin Gao, Lei Pei, Chenfei Lu, Huixin Sun, Yanxing Lai, Kang Du, Feizhe Xiao, Ying Yang, Xiuxing Wang, Yu Shi, Fan Bai, Nu Zhang
-
Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators Cancer Cell (IF 48.8) Pub Date : 2024-05-23 Zhanyu Wang, Chengming Liu, Sufei Zheng, Yuxin Yao, Sihui Wang, Xinfeng Wang, Enzhi Yin, Qingpeng Zeng, Chaoqi Zhang, Guochao Zhang, Wei Tang, Bo Zheng, Liyan Xue, Zhen Wang, Xiaoli Feng, Yan Wang, Jianming Ying, Qi Xue, Nan Sun, Jie He
-
The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy Cancer Cell (IF 48.8) Pub Date : 2024-05-23 Matheus Henrique Dias, Chrysa Papagianni, Rene Bernards
Most targeted cancer drugs inhibit the oncogenic signals to which cancer cells are addicted. We discuss here a counterintuitive approach to cancer therapy, which consists of deliberate overactivation of the oncogenic signals to overload the stress responses of cancer cells. We discuss why such overactivation of oncogenic signaling, combined with perturbation of the stress response pathways, can be
-
Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma Cancer Cell (IF 48.8) Pub Date : 2024-05-16 Hengkang Liu, Jiawen Gao, Mei Feng, Jinghui Cheng, Yuchen Tang, Qi Cao, Ziji Zhao, Ziqiao Meng, Jiarui Zhang, Guohong Zhang, Chong Zhang, Mingming Zhao, Yicen Yan, Yang Wang, Ruidong Xue, Ning Zhang, Hang Li
-
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy Cancer Cell (IF 48.8) Pub Date : 2024-05-16 Marit J. van Elsas, Jim Middelburg, Camilla Labrie, Jessica Roelands, Gaby Schaap, Marjolein Sluijter, Ruxandra Tonea, Vitalijs Ovcinnikovs, Katy Lloyd, Janine Schuurman, Samantha J. Riesenfeld, Thomas F. Gajewski, Noel F.C.C. de Miranda, Thorbald van Hall, Sjoerd H. van der Burg
-
Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer Cancer Cell (IF 48.8) Pub Date : 2024-05-13 Daniiar Dyikanov, Aleksandr Zaitsev, Tatiana Vasileva, Iris Wang, Arseniy A. Sokolov, Evgenii S. Bolshakov, Alena Frank, Polina Turova, Olga Golubeva, Anna Gantseva, Anna Kamysheva, Polina Shpudeiko, Ilya Krauz, Mary Abdou, Madison Chasse, Tori Conroy, Nicholas R. Merriam, Julia E. Alesse, Noel English, Boris Shpak, Anna Shchetsova, Evgenii Tikhonov, Ivan Filatov, Anastasia Radko, Anastasiia Bolshakova
-
Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis Cancer Cell (IF 48.8) Pub Date : 2024-05-13 Tarun Gupta, Agne Antanaviciute, Chloe Hyun-Jung Lee, Rosana Ottakandathil Babu, Anna Aulicino, Zoe Christoforidou, Paulina Siejka-Zielinska, Caitlin O’Brien-Ball, Hannah Chen, David Fawkner-Corbett, Ana Sousa Geros, Esther Bridges, Colleen McGregor, Nicole Cianci, Eve Fryer, Nasullah Khalid Alham, Marta Jagielowicz, Ana Mafalda Santos, Martin Fellermeyer, Simon J. Davis, Kaushal Parikh, Vincent Cheung
-
Understanding the complexity of p53 in a new era of tumor suppression Cancer Cell (IF 48.8) Pub Date : 2024-05-09 Yanqing Liu, Zhenyi Su, Omid Tavana, Wei Gu
p53 was discovered 45 years ago as an SV40 large T antigen binding protein, coded by the most frequently mutated TP53 gene in human cancers. As a transcription factor, p53 is tightly regulated by a rich network of post-translational modifications to execute its diverse functions in tumor suppression. Although early studies established p53-mediated cell-cycle arrest, apoptosis, and senescence as the
-
Immunotherapy in resectable NSCLC: Answering the question or questioning the answer? Cancer Cell (IF 48.8) Pub Date : 2024-05-02 Si-Yang Liu, Wei-Neng Feng, Yi-Long Wu
As immunotherapy makes its way into the perioperative setting, a growing number of clinical trials are expanding the evidence base for resectable non-small cell lung cancer (NSCLC) management. Identifying the optimal treatment pattern—whether it’s neoadjuvant, adjuvant, or a combination of both—is a crucial next step, particularly in pinpointing which patients benefit the most. This decision-making
-
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas Cancer Cell (IF 48.8) Pub Date : 2024-05-02 Jaewoo Choi, Michele Ceribelli, James D. Phelan, Björn Häupl, Da Wei Huang, George W. Wright, Tony Hsiao, Vivian Morris, Francesco Ciccarese, Boya Wang, Sean Corcoran, Sebastian Scheich, Xin Yu, Weihong Xu, Yandan Yang, Hong Zhao, Joyce Zhou, Grace Zhang, Jagan Muppidi, Giorgio G. Inghirami, Thomas Oellerich, Wyndham H. Wilson, Craig J. Thomas, Louis M. Staudt
-
Career trajectories of MD-PhD physician scientists: The loss of women investigators Cancer Cell (IF 48.8) Pub Date : 2024-05-02 Richard A. Steinman, Lisa M. Gandy, Hanfei Qi, Elana J. Fertig, Amanda L. Blackford, Jennifer R. Grandis
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women MD-PhD physician scientists are less likely to serve as principal investigators on mid- and later careers awards. Here, we discuss the causes of gender disparities in academic medicine, the implications of losing highly trained women
-
A temporal perspective for tumor-associated macrophage identities and functions Cancer Cell (IF 48.8) Pub Date : 2024-04-25 Camille Blériot, Garett Dunsmore, Direna Alonso-Curbelo, Florent Ginhoux
Cancer is a progressive disease that can develop and evolve over decades, with inflammation playing a central role at each of its stages, from tumor initiation to metastasis. In this context, macrophages represent well-established bridges reciprocally linking inflammation and cancer via an array of diverse functions that have spurred efforts to classify them into subtypes. Here, we discuss the intertwines
-
Molecular subtypes as potential biomarkers in renal cell carcinoma Cancer Cell (IF 48.8) Pub Date : 2024-04-25 Chadi Hage Chehade, Neeraj Agarwal
The increasing number of approved treatment combinations for metastatic renal cell carcinoma highlights the need for actionable biomarkers to guide treatment selection. In this issue of Cancer Cell, Saliby et al. validate the distinct clinico-genomic profiles of expression-based molecular clusters identified in the IMmotion151 trial in the JAVELIN Renal 101 dataset.
-
Tumor cell-intrinsic epigenetic SETpoint of cancer-associated fibroblasts Cancer Cell (IF 48.8) Pub Date : 2024-04-25 Xiongfeng Chen, Huocong Huang
Cancer-associated fibroblasts (CAFs) exhibit spatial and functional diversity. Here, Niu et al. unveil SETD2’s function in lipid metabolism and CAF heterogeneity in pancreatic ductal adenocarcinoma. SETD2 deficiency boosts oxidative phosphorylation activity, prompting lipid-laden CAF formation through BMP2 signaling, offering promising therapeutic avenues in personalized cancer treatment.
-
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers Cancer Cell (IF 48.8) Pub Date : 2024-04-25 Sarah T. Diepstraten, Yin Yuan, John E. La Marca, Savannah Young, Catherine Chang, Lauren Whelan, Aisling M. Ross, Karla C. Fischer, Giovanna Pomilio, Rhiannon Morris, Angela Georgiou, Veronique Litalien, Fiona C. Brown, Andrew W. Roberts, Andreas Strasser, Andrew H. Wei, Gemma L. Kelly
-
Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization Cancer Cell (IF 48.8) Pub Date : 2024-04-18 Wenying Wang, Tianran Li, Yue Cheng, Fei Li, Shuhong Qi, Min Mao, Jingjing Wu, Qing Liu, Xiaoning Zhang, Xuegang Li, Lu Zhang, Haoyue Qi, Lan Yang, Kaidi Yang, Zhicheng He, Shuaishuai Ding, Zhongyi Qin, Ying Yang, Xi Yang, Chunhua Luo, Ying Guo, Chao Wang, Xindong Liu, Lei Zhou, Yuqi Liu, Weikai Kong, Jingya Miao, Shuanghui Ye, Min Luo, Lele An, Lujing Wang, Linrong Che, Qin Niu, Qinghua Ma, Xia Zhang
-
The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia Cancer Cell (IF 48.8) Pub Date : 2024-04-11 Mingyang Liu, Yu Ren, Zhijun Zhou, Jingxuan Yang, Xiuhui Shi, Yang Cai, Alex X. Arreola, Wenyi Luo, Kar-Ming Fung, Chao Xu, Ryan D. Nipp, Michael S. Bronze, Lei Zheng, Yi-Ping Li, Courtney W. Houchen, Yuqing Zhang, Min Li
-
Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer Cancer Cell (IF 48.8) Pub Date : 2024-04-08 Hui Yang, Jinghui Cheng, Hao Zhuang, Hongchuang Xu, Yinuo Wang, Tingting Zhang, Yinmo Yang, Honggang Qian, Yinying Lu, Feng Han, Lihua Cao, Nanmu Yang, Rong Liu, Xing Yang, Jiangong Zhang, Jianmin Wu, Ning Zhang
-
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis Cancer Cell (IF 48.8) Pub Date : 2024-04-08 Darko Barisic, Christopher R. Chin, Cem Meydan, Matt Teater, Ioanna Tsialta, Coraline Mlynarczyk, Amy Chadburn, Xuehai Wang, Margot Sarkozy, Min Xia, Sandra E. Carson, Santo Raggiri, Sonia Debek, Benedikt Pelzer, Ceyda Durmaz, Qing Deng, Priya Lakra, Martin Rivas, Christian Steidl, David W. Scott, Ari Melnick
Abstract not available